TruthArchive.ai - Related Video Feed

The speaker presents an illustration of clots removed from a 30-year-old man, noting the largest clot came from the femoral artery while two of the smaller clots came from the radial arteries. The footage is described as zoomed in so viewers can see that these clots are not natural and have come from inside the arteries. The speaker emphasizes that these clots are not a normal finding inside a young man of 30 years old, repeatedly asserting that “these are not natural” and “these shouldn’t be inside this young man of 30 years old.” The presenter then remarks that the case is “imprisoned and deceased in The UK,” linking the observation to events or revelations associated with Richard Hirschman. The speaker indicates an attempt to examine the clots more closely, explaining the lack of equipment (no microscope) but insisting on the visible reality of clots sitting inside the arteries, and rhetorically questions whether this is normal. The final claim made is that the individual from whom the clots were removed was a jab recipient, tying the medical observation to vaccination. Throughout, the speaker frames the findings as alarming and abnormal, stressing the combination of young age, arterial clots, and a vaccination context, while invoking Hirschman’s revelations and noting the location as The United Kingdom.

Speaker: A lot of the analysis techniques that were being employed now on the white clots. And about three years ago, there was one piece of analyses that I came across just by accident, which was a thing called an ICP analysis, which is an analysis that determines the elements present in white clots. It was done by a gentleman in The USA called Mike Adams, who presented the findings of his initial white clot analysis from samples that Richard had provided him some almost three years ago now. And it surprised me what the findings were, because I have used the ICP analysis. It’s called Inductively Coupled Plasma Mass Spectrometry. Don't worry about the name. It's just a very well known piece of analytical equipment that you can rely upon to tell you what elements are there in the white clot and in what abundance. And what surprised me was in the analysis that Mike presented was a very the highest element they found was phosphorus, followed by sodium, tin, and later on sulphur, and carbon. And we also found that there were no normal blood marker elements present in the white clots. So, we've actually employed two laboratories in Europe, and there's a long reason behind that because I'm associated with people in Europe who do this kind of work. Anyway, we sent clot samples, they all ran ICP analyses. They found exactly the same results that Mike Adams found. We found aberrantly high levels of phosphorus, we found aberrantly high levels of sulphur, tin, sodium, and carbon. And being an organic chemist, I know a little bit about tin chemistry, because I used to sell tin catalysts, believe it or not, for polymerisation reactions. So I had to study the chemistry of tin. And I wondered why tin would be present in a white clot. So, obviously, we could not believe this first series of results. It's set about replicating the results in two separate labs, and they came back and said, you're right, there's high levels of phosphorus, tin, sulfon, carbon. So the next thing we did was to do an analysis called HPLC, High Performance Liquid Chromatography. And what this does is actually pulls apart the white clots and tells you what the protein components are. And surprisingly, we found that the highest level of proteins we found was fibrinogen. But the HPLC analysis actually will determine what kinds of fibrinogen chains are there. In a normal red blood clot, there's normally one to one to one ratio of the alpha chain, beta chain and gamma chain. We found in our white clots that the beta chain far exceeded the alpha chain and the gamma chain. And in fact, it was beta gamma alpha. So the alpha was the lowest proportion. Now, we're not biochemists, and we're not medically qualified in any way. But we can do simple research to find out why the fibrinogen content was so high. Fibrinogen forms fibrils. This is exactly why when John O'Learny first described the white clots as being calamari like, he is exactly correct. That's exactly the texture that fibrin will bring into a white clot. Okay, so from then on, we then ran some amino analysis results. My colleagues ran an amino acid analysis, and they found a high level of Praline, Aspartic acid, Lysine, a whole range of about 18 amino acids, all that have a phosphorus affinity. And as we said in the white clot, the element that has the highest concentration that we could confirm is porpoise. If you take time then to research the aberrant pathways that what they call excess phosphorylation will cause, it causes a whole range of problems in the human body. So we have determined, we think, the pathway to the formation of these white clots. We have three separate pieces of analysis, all confirming our findings. So we've now pieced together the formation of the white clots, and I'll come back to the very beginning. When we administer the injections, there is a lipid nanoparticle carrier, it's called a phospholipid. We found by our analysis that when the phospholipid releases the mRNA core of the lipid nanoparticle, at the very moment that it releases the core, it actually exposes a phosphorus head of the phosphorus lipid. The phosphor lipid reacts within the bloodstream naturally formed fibrinogen, and that's what's nucleating the white clot formation. Now we can prove all this. We've actually got over 200 peer reviewed papers confirming the pathway that I'm describing. And more importantly, once that initiation of the DSPC now the actual phospholipid that is encapsulating the lipid nanoparticle is a phospholipid called DSPC. I won't go into the name of it, but what it means is that that particular phospholipid we found, again through research, that it will liberate 80 to 90% of raw phosphorus heads as it releases the mRNA core. Those phosphorus heads all react with the fibrinogen in the bloodstream and they cause sandy blood. The reason you guys are seeing sandy blood and coffee grounds is that's the nucleation pathway to the final white clot formation. The other factor we found and proved the spike protein bonds to the phosphorylated fibrinogen. The body is generating methylcetiopridine generated spike, that spike in the bloodstream then starts to coagulate with the phosphorylated fibrinogen, and that feeds what we call a monomeric reaction that continues to grow. Those particles are free flowing in the blood and they find an anchor point. The anchor points they find are in fact the damaged endothelial layers. When an endothelial layer of the vascular system is damaged via inflammation and the cytokine storm that the spike protein generates, That opens up the natural phospholipid layer of the endothelial layer, and that forms anchor points for these nuclei. From these anchor points, that's when the clots begin to grow. So, I'm trying to encapsulate this in a very simple term. It's quite a complex number. Very

In this video, the speaker discusses the presence of white fibrous clots in bodies. They conducted a survey last year to determine if this phenomenon was real. The survey revealed that around 70% of embalmers were seeing these clots, with most of them noticing them after the rollout of vaccines in 2021. Some embalmers reported seeing these clots in up to 50% or more of the corpses they worked with. The speaker is currently conducting another survey to gather more information on what embalmers are observing in 2023.

Tom Haviland, a retired major in the US Air Force and an experienced embalmer, discusses the presence of white fibrous clots found in the circulatory systems of deceased individuals. These clots, which have been observed in a high percentage of corpses over the past three years, are believed to be made of amyloid protein and fibrin. Embalmers have noticed an increase in the size and prevalence of these clots, as well as an increase in microclotting or "coffee ground" clots. The data collected from embalmers suggests that these clots may be linked to the spike protein produced by the COVID-19 vaccines.

Genes from injected vaccines enter bloodstream and cells lining vessel walls, producing spikes. Lymphocytes attack these cells, leading to clot formation. Antibodies appear after 3-4 weeks, attacking vessel wall cells. Vaccination creates unique situation with unknown outcome. Advises against second or any future shots due to potential dangers revealed in recent publications. Calls for discussion and action to address potential risks.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

There have been reports of blood clots in patients who have received the vaccine. These clots have been found in living patients and have also been observed in post-mortem examinations. The clots are made up of fibrous material and unusual combinations of proteins that make them difficult for the body to dissolve. However, it is important to note that not everyone who receives the vaccine will experience these clots. One possible solution is the use of an enzyme called Nattokinase, derived from fermented soy, which has been shown to break down fibrin and dissolve clots. Further research is needed to fully understand and address this issue.

The clots being formed, we've run mass spectrometry on these clots. They don't look like normal clots. They don't have the same composition. They don't have fibrin. They don't have thrombin, which are normal things you would see in a normal coagulation cascade. They have, instead, all the fibrinogen chains—alpha, beta, and gamma. They have them in a strange differential where it's not one-to-one-to-one; it's about 36 to 16 to 4 by ratios. They're aberrantly cross-linked by sulfide bonds. There's a ton of tin for some reason. I don't know why there's tin in there, but there's a ton of tin in there and a ton of phosphorus. And the spike protein is actually coated in GLIKNAK, which is a phosphate donor. So that might explain all the phosphorus if it's providing the energetics or in some way by cleaving or creating phosphate bonds. So I think that that's a big problem because that's a slow progression of coagulopathy that's, I think, narrowing the lumens of the vascular system, which is contributing to some of the organ failure that we're seeing, some of the neurological symptomatology that we're seeing, some of the fatigue, and things of that nature. And then finally, the spike protein is shown to produce—it’s shown to induce misfolding of proteins and actually

The speaker discusses how the spike protein in vaccines can lead to clotting issues, immune suppression, and reactivation of latent viruses like mono. This can also weaken the body's ability to fight off other viruses and cancers. An increase in cancer cases post-vaccination is noted anecdotally. The speaker attributes these effects to the spike protein in the vaccines.

In the past, we did not see blood clotting like this before COVID-19 vaccinations. A marathon runner had severe issues walking after vaccination, requiring treatments like plasma freezes. Clot formations indicate ongoing damage to blood vessel linings, leading to clot formation. Multiple vaccinated individuals experience circulation problems in cold temperatures, with symptoms improving in warmer weather.

A UK doctor and a US cardiologist have whistleblowers revealing an increase in white fibrous clots being removed from patients. Traditional clot-busting drugs are ineffective against these clots, requiring manual extraction in cath labs. The whistleblowers link the presence of these clots to COVID vaccine recipients, with 99% of patients having received 1 to 8 doses. The issue worsens with more vaccine doses. The whistleblowers fear repercussions for speaking out.

The data indicates that vaccinations have led to serious health issues, including blood clots, strokes, and amputations. A simple d-dimer test can reveal the presence of blood clots, yet the government has not mandated this test for vaccinated individuals. Studies by two cardiologists found that over 80% of vaccinated patients had elevated d-dimer levels, suggesting microemboli, which can cause gradual organ failure and increase the risk of severe thrombosis, particularly in the brain. Cases of thrombosis in young people are rising, likely due to microemboli and the spike protein from the vaccine affecting blood vessel walls. This connection has been established through clinical observations.

In this video, Richard Hirschman, an embalmer, discusses the abnormal blood clotting issues he has observed in bodies since early 2021. He shares that these clots are different from typical blood clots, as they are white, fibrous, and rubbery in texture. Hirschman believes that these clots may be caused by aberrant proteins resulting from the COVID vaccines. He emphasizes the need for further research and understanding of these clots and their potential impact on health. Another guest, Jamie, a funeral service professional, supports Hirschman's observations and urges people to critically evaluate the situation. The video also includes a discussion on the suppression of information and the need for scientific investigation.

Our study investigates the impact of the SARS-CoV-2 spike protein on blood hypercoagulation. We used microscopy and mass spectrometry to examine the spike protein's interaction with platelets and fibrinogen. Results using platelet-poor plasma showed the spike protein may disrupt blood flow. Mass spectrometry revealed structural changes in beta and gamma fibrinogen, complement, and prothrombin after adding spike protein S1. These changes, similar to those observed in COVID-19 patient blood clots, showed resistance to trypsinization. We propose that the spike protein's presence in the bloodstream contributes to hypercoagulation in COVID-19 patients, potentially causing impaired fibrinolysis and persistent microclots. This finding has significant clinical implications. Our goal was to determine the spike protein's effects, as its interaction with these blood components warrants further investigation.

D-dimers are markers for thrombosis. When analyzing blood samples for suspected deep vein thrombosis or pulmonary embolism, the normal range should not exceed 500. However, there has been a significant increase in elevated d-dimers among vaccinated patients. Many patients have levels above 3000, leading to concerns about microthrombosis throughout the body. Despite further examinations, no embolism or thrombosis has been found. Fatigue is a common symptom among these patients. The risk is that these individuals may experience microthromboses, potentially leading to death in the future. This raises questions about the future health and insurability of those with high d-dimer levels. Investigations and studies should be conducted to understand these phenomena, including the occurrence of thrombosis in placentas during pregnancies.

There are real cases of blood clots in patients who have received the vaccine. These clots are thick and fibrous and can be seen in living patients. A tube of blood from a patient with cold-induced finger pain showed the same fibrils as the clots. The body has difficulty breaking down the material in the clots, including amyloid. Autopsies were discouraged early on, so these clots may not have been discovered. Morticians have noticed unusual back pressure when preserving bodies. The clots contain collected proteins and unusual combinations that are hard to dissolve. Nattokinase, an enzyme found in fermented soy, can break down fibrin and may be helpful in dissolving clots.

The spike protein, according to research in South Africa, induces fibrin from fibrinogen, forming the backbone of clotting in a way not previously seen. Unlike normal fibrin clots that are easily broken down, clots formed from COVID or the spike protein from the vaccine are difficult to break down, causing issues for many people. A cardiologist stated that in their decades of practice, they have never treated as many blood clots as in the last five years. These blood clots occur after the virus infection and the vaccine because the spike protein causes blood clots. Therefore, it is reckless to continue vaccinating people and loading the body with spike protein, causing more blood clots. According to a paper in Cell (July 2021), the nucleoprotein, not the spike protein, supplied broad and durable immunity for the prevention of infection. The speaker questions why the vaccine wasn't changed to target the nucleoprotein once this information came to light.

I recently conducted a survey of embalmers, and 73% of the 269 respondents reported finding white fibrous clots in corpses during 2023. These clots, which consist of fibrin, platelets, and amyloid-like material, are suspected to be a contributing factor in strokes and heart attacks. Embalmers are finding these clots are making it necessary to use multiple injection sites, lengthening the embalming process. While similar clots were observed in 2020, during the initial COVID outbreak, their prevalence exploded with the introduction of vaccines in 2021. The spike protein from the virus and vaccines may be responsible for the formation of these clots. Additionally, embalmers are reporting increases in microclotting and traditional grape jelly clots. One theory suggests "frame shifting," where ribosomes misread the modified RNA code from vaccines, creating aberrant proteins that form amyloid material. I can be contacted at thomashaveland@sbcglobal.net.

White fibrous clots found in the living and dead recipients of mRNA vaccines are being ignored, but research reveals their composition and cause. The spike protein mutates fibrin into jagged, misfolded, insoluble amyloid, similar to prionic infections. Microclots form and align into large white clots, initiated by spike protein fragments like spike 601. Prolene, a "kinker protein" added to the spike protein, causes misfolding, with proline being prevalent in the clots. A 2021 paper showed the SARS CoV-2 spike induces abnormal blood clots due to the fibrinogen beta chain. Plasma exposed to the spike protein is imbalanced, with the fibrinogen beta chain being dominant. These clots contain four times the normal amount of phosphorus, released from lipid nanoparticles. Similar clots in 1988 were caused by sulfur-based heparin, which was resolved by reducing sulfur content. A 2017 paper showed altered phosphorus levels cause cancer. Thomas Havilland, who shares this information, is being ignored by mainstream and alternative media. Undertakers are seeing massive white fibrous clots at record levels.

They said stroke only happened to the old, but hospitals started seeing something new. Healthy people suddenly clotting. Coincidence? Maybe. But after 2021, studies began tracing small patterns, inflammation, platelets, micro clots weeks after certain shots. Most never notice but for a few, the immune system hits too hard. The same spike that's meant to protect starts sticking to vessel walls. Breath thickens, flow slows, boom. Ischemia. Doctors call vaccine induced immune thrombotic events. Rare, yes, imagined, no. Its indolentacid and negem. The question isn't if it happens but why somebody's break the code. Genetics, guts, toxins, maybe all three. Because when the system builds to defend starts to misfire the result isn't protection, it's a stroke.

The speaker has been sequencing clots and found real human DNA, showing a signature of neutrophil extracellular traps, a reaction occurring in sepsis when the immune system clots around foreign entities. This process takes free-circulating DNA into clotting structures, leaving a specific signature. Sequencing reveals patient genome sequences that might predispose them to clotting. While billions received shots, not everyone clotted, suggesting a subset has a bad reaction. Genetic predispositions in the clotting cascade may increase risk. Initial analysis of two clots shows high-impact variants in genes involved in fibrin formation and clotting. Kevin McCarran's work demonstrates some clots bind thiophlavin, a marker for amyloid, suggesting a potential amyloidosis issue. Pathology needs careful examination as it may underlie clotting problems. This information is being suppressed, but citations are provided for reference.

The speaker discusses the formation of clots induced by the spike protein in the blood. These clots can be white and fibrous, and they can vary in size. The speaker mentions that these clots can lead to heart attacks or strokes if they block the flow of oxygen in the body. They also mention an enzyme called Nattokinase, derived from fermented soy, which can break down fibrin and dissolve clots. The speaker suggests that using enzymatic mechanisms to break down clots early can prevent the accumulation of amyloid proteins and the worsening of clots.

Speaker 0 describes an ICP analysis (Inductively Coupled Plasma Mass Spectrometry) of white clots, initially encountered about three years ago from samples provided by Richard. Mike Adams presented the initial findings. The ICP analysis showed the highest element in the white clots was phosphorus, followed by sodium, tin, then sulfur and carbon. They also found that there were no normal blood marker elements present in the white clots. Two laboratories in Europe were used to replicate the results; both reported aberrantly high levels of phosphorus, tin, sulfur, sodium, and carbon. To investigate further, they performed High Performance Liquid Chromatography (HPLC) to identify protein components. The highest level of protein found was fibrinogen. The HPLC analysis determined the kinds of fibrinogen chains present, and it showed that in the white clots the beta chain far exceeded the alpha and gamma chains, with a beta-gamma-alpha ratio. They noted they were not biochemists or medically qualified, but conducted simple research to understand why fibrinogen content was so high. Fibrinogen forms fibrils, which aligns with John O’Learny’s description of white clots as calamari-like in texture, matching the expected texture from fibrin. An amino acid analysis by colleagues revealed high levels of proline, aspartic acid, lysine, and about 18 other amino acids, all with phosphorus affinity. They reiterate that the element with the highest confirmed concentration in the white clot is phosphorus. They state that aberrant phosphorylation pathways can cause a range of problems in the human body. They claim three separate pieces of analysis confirm their findings, allowing them to piece together the pathway to the formation of white clots. They connect this to injections that use a lipid nanoparticle carrier, specifically a phospholipid. Their analysis indicates that when the phospholipid releases the mRNA core of the lipid nanoparticle, it exposes a phosphorus head of the phospholipid. The phospholipid reacts within the bloodstream with naturally formed fibrinogen, nucleating the white clot formation. They claim over 200 peer-reviewed papers confirm the pathway described. They specify that the DSPC phospholipid encapsulating the lipid nanoparticle liberates 80 to 90% of raw phosphorus heads as it releases the mRNA core. Those phosphorus heads react with fibrinogen in the bloodstream, causing the sandy blood and coffee-ground appearance as the nucleation pathway to final white clot formation. They add that the spike protein binds to phosphorylated fibrinogen; the body generates methylcetiopridine-generated spike protein in the bloodstream, which coagulates with phosphorylated fibrinogen, feeding a monomeric reaction that continues to grow. These particles are free-flowing in the blood and find anchor points on damaged endothelial layers. When endothelial layers are damaged via inflammation and the cytokine storm induced by the spike protein, the natural phospholipid layer of the endothelium opens up and forms anchor points for these nuclei. From these anchor points, the clots begin to grow. They acknowledge the complexity but describe this as a simple encapsulation of the process.

The speaker claims injections result in blood clots, stroke, heart attack, and lost limbs, and questions why the government hasn't ordered D-dimer tests for vaccinated individuals to assess blood clot risk. Two cardiology studies allegedly found over 80% of vaccinated patients had high D-dimer levels, indicating microemboli. Microemboli in the brain, heart, or kidneys can cause organ failure and increase susceptibility to disease, potentially leading to strokes. The speaker reports seeing more cases of thrombosis of the superior sagittal sinus and transverse sinus in the brain, particularly in young people. They attribute this to microemboli and embolism caused by the spike protein from the vaccine and a nanolipid carrier entering the blood vessel wall, which they claim has been proven.